Breaking News Instant updates and real-time market news.

PFE

Pfizer

$45.71

0.2 (0.44%)

11:30
11/30/18
11/30
11:30
11/30/18
11:30

Size spread in Pfizer as a call write is adjusted

Size spread in Pfizer as a call write is adjusted. The stock up 29c to $45.80 and 13K Jan 46 - 48 call spreads sold at 87c. Size matches a position from 10/10 when a seller opened 13K Jan 46 calls at $1.30 (rolling out of Dec 44 calls with shares near $44.50). The calls are covered today at $1.30, as shares reach new 52-week highs, and a new position opened in Jan 48 calls at 43c, which is likely an overwrite against a position in the underlying. Earnings out 10/30 and not due again until late-January.

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

  • 18

    Dec

PFE Pfizer
$45.71

0.2 (0.44%)

11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.

TODAY'S FREE FLY STORIES

CPE

Callon Petroleum

$4.47

-0.175 (-3.77%)

, CRZO

Carrizo Oil & Gas

$7.73

-0.21 (-2.64%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Hot Stocks
Callon Petroleum, Carrizo Oil & Gas announce amendment to merger agreement »

Callon Petroleum (CPE)…

CPE

Callon Petroleum

$4.47

-0.175 (-3.77%)

CRZO

Carrizo Oil & Gas

$7.73

-0.21 (-2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

GECC

Great Elm Capital

$8.23

-0.02 (-0.24%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Earnings
Great Elm Capital reports Q3 NII 26c, consensus 25c »

Net assets on September…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

, SANM

Sanmina

$32.76

0.26 (0.80%)

06:13
11/14/19
11/14
06:13
11/14/19
06:13
Recommendations
Cisco, Sanmina, Flex, Jabil analyst commentary  »

Cisco results negative…

CSCO

Cisco

$48.44

0.06 (0.12%)

SANM

Sanmina

$32.76

0.26 (0.80%)

FLEX

Flex

$12.33

0.39 (3.27%)

JBL

Jabil

$39.27

0.28 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

BCLI

BrainStorm

$3.88

0.05 (1.31%)

06:12
11/14/19
11/14
06:12
11/14/19
06:12
Earnings
BrainStorm reports Q3 EPS (25c), consensus (22c) »

"On October 11, 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 11

    Dec

RMBL

RumbleON

$1.50

-0.83 (-35.62%)

06:11
11/14/19
11/14
06:11
11/14/19
06:11
Recommendations
RumbleON analyst commentary  »

RumbleON price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AXNX

Axonics

$25.49

0.53 (2.12%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Hot Stocks
Axonics announces FDA approval of Axonics r-SNM System »

Axonics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

EPAM

Epam Systems

$200.74

0.85 (0.43%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FENG

Phoenix New Media

$3.04

0.04 (1.33%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Phoenix New Media declares 17.14c per share special cash dividend »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.37

0.04 (3.01%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Athersys: Healios receives orphan designation for ARDS clinical program »

Athersys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:06
11/14/19
11/14
06:06
11/14/19
06:06
Recommendations
Cisco analyst commentary  »

Piper stays on sidelines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

GRUB

GrubHub

$36.63

-0.7 (-1.88%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Periodicals
GrubHub to create 'task force' after NYC Council threatens action, NYP says »

GrubHub will create a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTT

Wireless Telecom Group Inc

$1.50

0.04 (2.74%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Hot Stocks
Wireless Telecom Group Inc to Acquire Holzworth Instrumentation »

Wireless Telecom Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FVRR

Fiverr

$22.55

0.99 (4.59%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Fiverr rating change  »

Fiverr upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

ROLL

RBC Bearings

$165.06

-1.19 (-0.72%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Downgrade
RBC Bearings rating change  »

RBC Bearings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$155.38

-2.295 (-1.46%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

NRZ

New Residential

$16.06

-0.07 (-0.43%)

06:03
11/14/19
11/14
06:03
11/14/19
06:03
Downgrade
New Residential rating change  »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$2.50

0.04 (1.63%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Earnings
New Age Beverages reports Q3 EPS (14c), consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Periodicals
SoftBank's Yahoo Japan in talks to merge with Naver's Line, Nikkei reports »

SoftBank's Yahoo…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:01
11/14/19
11/14
06:01
11/14/19
06:01
Recommendations
Cisco analyst commentary  »

Citi keeps Buy on Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XRX

Xerox

$37.60

0.14 (0.37%)

, HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

06:00
11/14/19
11/14
06:00
11/14/19
06:00
Periodicals
Carl Icahn pushes for Xerox, HP Inc union, WSJ reports »

Carl Icahn, who owns a…

XRX

Xerox

$37.60

0.14 (0.37%)

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

MYO

Myomo

$0.54

-0.1126 (-17.26%)

05:58
11/14/19
11/14
05:58
11/14/19
05:58
Downgrade
Myomo rating change  »

Roth Capital downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

05:57
11/14/19
11/14
05:57
11/14/19
05:57
Syndicate
Fulgent Genetics 2.325M share Spot Secondary priced at $11.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ECOR

electroCore

$1.88

0.06 (3.30%)

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

electroCore

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:55
11/14/19
11/14
05:55
11/14/19
05:55
Conference/Events
SunTrust hosted company meetings at conference »

SunTrust hosted Meetings…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.